Apixaban: an oral direct factor-xa inhibitor. - Wikidata - awgldk - TriplyDB

Apixaban: an oral direct factor-xa inhibitor.

Apixaban: an oral direct factor-xa inhibitor.

http://www.wikidata.org/entity/Q37987051

about

Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban, apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment.

P2860

Q38079779-A0A6554A-6197-440B-8886-DE676EF84E02

P2860

Apixaban: an oral direct factor-xa inhibitor.

http://www.wikidata.org/entity/Q37987051

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Apixaban: an oral direct factor-xa inhibitor.

@en

Apixaban: an oral direct factor-xa inhibitor.

@nl

type

label

Apixaban: an oral direct factor-xa inhibitor.

@en

Apixaban: an oral direct factor-xa inhibitor.

@nl

prefLabel

Apixaban: an oral direct factor-xa inhibitor.

@en

Apixaban: an oral direct factor-xa inhibitor.

@nl

P1433

Q37987051-D24503F0-89E4-4A56-B30B-6FD5DD94FD20

P1476

Q37987051-B453CF50-7F0B-430E-91B4-407735BA7D1B

P2093

Q37987051-573BFFC5-4BAF-42A1-AE19-DBB113C6BBB8

Q37987051-A83752B2-5D45-4193-B8EE-13F004A6C063

Q37987051-D0C00E43-6032-4BEF-9D0E-1D62907BD76E

P2860

Q37987051-10299F42-F288-4FB3-B447-6198D2578401

Q37987051-189B06C6-421D-4748-8A15-B2E4135709AE

Q37987051-252C4AD8-4F90-48AA-BC11-1C939D9FB92E

Q37987051-2988832B-E574-4859-AE0E-F54EDED8E31E

Q37987051-3983155B-4886-4A5C-B4E5-AB12A047F02D

Q37987051-39B22259-0B28-407C-B828-84B924158B74

Q37987051-39D614D7-F376-4BC4-B828-4384B75C9D6F

Q37987051-46245993-70DE-4598-8C20-8EDC4552C088

Q37987051-5389A23D-57D5-4890-91AF-58C7A6443BF8

Q37987051-543CEF66-2AF8-43EA-AE87-BDF3A77E7E23

P2888

Q37987051-CCDA42C4-3D7E-4133-9AAA-5322F6073AB5

P304

Q37987051-FAD20ECA-9F30-445B-9E1F-826A25A20CF0

P31

Q37987051-82521591-7DAF-44CC-8DED-1ACF88316546

P356

Q37987051-4193D889-4488-44BF-B92A-8A8C4395AD6B

P407

Q37987051-B162DFA8-BDF6-473C-AE33-DEF301D0D303

P433

Q37987051-279135F1-542D-4B0A-9987-786C8CDFA005

P478

Q37987051-4C9440FA-ED52-4BC4-890B-1135E0A5F5A6

P577

Q37987051-6DFF2C76-F201-47E0-A571-89B34896961F

P698

Q37987051-705E86E4-2014-44BA-9917-ACB6B4652E0E

P356

S12325-012-0003-2

P1433

Advances in Therapy

P1476

Apixaban: an oral direct factor-xa inhibitor.

@en

P2093

David Jiménez

http://www.w3.org/2001/XMLSchema#string

Eduardo Ramacciotti

http://www.w3.org/2001/XMLSchema#string

Roger D Yusen

http://www.w3.org/2001/XMLSchema#string

P2860

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

Apixaban versus warfarin in patients with atrial fibrillation

Apixaban metabolism and pharmacokinetics after oral administration to humans.

Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

Apixaban in patients with atrial fibrillation.

P2888

s12325-012-0003-2

P304

187-201

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-012-0003-2

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22354465

http://www.w3.org/2001/XMLSchema#string